Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06417177 · ClinicalTrials.gov registry record · Early Phase 1

Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia

A Early Phase 1 study of Aging and Menopause, sponsored by University of Missouri-Columbia.

Recruiting
Registry status
Early Phase 1
Development phase
75
Enrollment target
1
Study location

NCT06417177 is a Early Phase 1 study of Aging and Menopause that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 75 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06417177, a Early Phase 1 study of Aging and Menopause, is actively recruiting participants, sponsored by University of Missouri-Columbia.

RECRUITING
Registry status
Early Phase 1
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine hypoxic vasodilation and the role of beta-adrenergic receptors in younger premenopausal, perimenopausal, and older postmenopausal women.

Interventions

  • DRUG Placebo
  • DRUG Propranolol
  • DRUG Gemtesa

Study Locations (1)

Missouri

  • University of Missouri-Columbia - Columbia

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2024-06-03
Est. Completion 2026-07
Phase Early Phase 1

Sponsor

University of Missouri-Columbia

291 total trials

What the Registry Record Tells You About NCT06417177

The ClinicalTrials.gov registry entry for NCT06417177 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower). The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Aging appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06417177 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT06417177 about?

NCT06417177 is a clinical study titled "Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia". The purpose of this study is to examine hypoxic vasodilation and the role of beta-adrenergic receptors in younger premenopausal, perimenopausal, and older postmenopausal women.

What is the current status of trial NCT06417177?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 75 participants. The study started on 2024-06-03. Estimated completion is 2026-07.

What conditions does trial NCT06417177 study?

This clinical trial studies the following conditions: Aging, Menopause, Hypoxia, Vasodilation.

What interventions are being tested in trial NCT06417177?

The interventions under investigation include: Placebo (DRUG), Propranolol (DRUG), Gemtesa (DRUG).

Who is sponsoring clinical trial NCT06417177?

This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06417177 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.